Amivantamab demonstrated modest activity and disease stabilization in R/M ACC patients, with a manageable safety profile predominantly marked by rash and infusion reactions. While it fell short of ORR goals and P63/MYC were not predictive of benefit, these results highlight its potential role in a challenging, treatment-resistant setting.

The ARC-20 study highlights the potential of casdatifan, a novel HIF-2α inhibitor, combined with cabozantinib in previously treated metastatic clear cell RCC. As this promising combination advances into Phase III and a pivotal trial, it may redefine practice and provide a powerful new option for patients with mRCC.

The CheckMate 901 trial evaluated the immunotherapy combination of OPDIVO (nivolumab) plus YERVOY (ipilimumab) versus standard gemcitabine and carboplatin in cisplatin-ineligible patients with previously untreated unresectable or metastatic urothelial carcinoma. While the trial did not meet its predefined threshold for statistical significance in overall survival, OPDIVO + YERVOY demonstrated clinically meaningful benefits, including longer median OS, improved long-term progression-free survival, and extended duration of response.

BioAtla’s Phase II data spotlight ozuriftamab vedotin as a potent, well-tolerated option for heavily pretreated HPV+ OPSCC, including anti–PD-1–refractory cases. The strong efficacy and safety signal pave the way for Phase III trials and potential accelerated approval.

Eli Lilly’s updated Phase III data for Imlunestrant confirm its potential as both monotherapy and in combination with abemaciclib for HR+/HER2−advanced breast cancer. It demonstrated a favorable safety profile and meaningful PFS improvements, particularly in ESR1-mutant patients, underscoring the potential of SERD-based combination strategies.

PF-08046054 in combination with pembrolizumab demonstrated encouraging safety and antitumor activity in R/M HNSCC, including a 50% ORR and 21.4% CR rate. These early results support continued clinical development of the combination as a promising therapeutic approach.